Published in Blood Weekly, December 10th, 2009
"SAK-HV maintained fibrinolytic activity similar to SAK and had anticoagulant activity attributable to its hirudin segment. of thrombin-binding activity in vitro demonstrated that SAK-HV possessed binding activity with thrombin while SAK did not," wrote M. Wang and colleagues.
The researchers concluded:...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.